Neutralizing IL-23 or IL-17 therapeutic strategies appear to have a good impact on immune-mediated inflammatory disorders such as psoriasis, multiple sclerosis, and rheumatoid arthritis (RA) [8]. Here, IL17A is linked to rheumatoid arthritis.